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Abstract
Aims: Several neurodegenerative disorders show alterations in glutamatergic synapses and increased susceptibility to
excitotoxicity. Mounting evidence suggests a central role for the cellular prion protein (PrPC) in neuroprotection.
Therefore, the loss of PrPC function occurring in prion disorders may contribute to the disease progression and
neurodegeneration. Indeed, PrPCmodulatesN-methyl-d-aspartate receptors (NMDAR), thus preventing cell death. In
this study, we show that PrPC and copper cooperatively inhibit NMDAR through S-nitrosylation, a post-translational
modification resulting from the chemical reaction of nitric oxide (NO) with cysteines. Results: Comparing wild-type
Prnp (Prnp+/+) and PrPC knockout (Prnp0/0) mouse hippocampi, we found that GluN1 and GluN2A S-nitrosylation
decrease in Prnp0/0. Using organotypic hippocampal cultures, we found that copper chelation decreases NMDAR S-
nitrosylation in Prnp+/+ but not in Prnp0/0. This suggests that PrPC requires copper to support the chemical reaction
between NO and thiols. We explored PrPC-Cu neuroprotective role by evaluating neuron susceptibility to ex-
citotoxicity in Prnp+/+ and Prnp0/0 cultures. We found that (i) PrPC-Cu modulates GluN2A-containing NMDAR,
those inhibited by S-nitrosylation; (ii) PrPC and copper are interdependent to protect neurons from insults; (iii)
neuronal NO synthase inhibition affects susceptibility in wild-type but not in Prnp0/0, while (iv) the addition of a NO
donor enhances Prnp0/0 neurons survival. Innovation and Conclusions: Our results show that PrPC and copper
support NMDAR S-nitrosylation and cooperatively exert neuroprotection. In addition to NMDAR, PrPC may also
favor the S-nitrosylation of other proteins. Therefore, this mechanism may be investigated in the context of the
different cellular processes in which PrPC is involved. Antioxid. Redox Signal. 22, 772–784.
Introduction
The cellular prion protein (PrP
C) has been extensively
investigated since its isoform, the prion, was identified as
the causative agent of prion disorders (33). PrPC is widely ex-
pressed, reaching the highest levels in the nervous system (3, 12,
31). Comparing wild-type with PrPC-null mice (Prnp0/0) has
revealed that PrPC expression at synapses contributes to hippo-
campus synaptic function (6, 27, 28) and exerts neuroprotection
by modulating neuronal excitability (21, 34, 38). In particu-
lar, PrPC inhibits N-methyl-d-aspartate receptors (NMDAR)
and requires copper for this effect (21, 40). Interestingly, Ab
oligomers induce neurotoxicity by blocking PrPC-Cu modu-
lation of NMDAR (40). Impairments in NMDAR regulation
induce excitotoxicity, the neuronal cell death pathway trig-
gered by massive calcium influx (10). Calcium ions enter the
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cell through the NMDAR channel and bind several interactors,
for example, calmodulin (CaM). Calcium-bound CaM acti-
vates neuronal nitric oxide synthase (nNOS) and induces cop-
per-transporting ATPase 1 (Atp7a) translocation, thus leading
to nitric oxide (NO) production and copper release in the
synaptic cleft (22, 36). Copper and NO modulate the NMDAR
activity through a not clearly defined mechanism: NMDAR S-
nitrosylation provides a link between copper and NO inhibitory
roles (7, 23). S-nitrosylation is a chemical post-translational
modification targeting protein cysteines. In NMDAR, S-
nitrosylation is inhibitory and addresses two residues on GluN1
and three residues on GluN2A, including Cys399, which me-
diates the predominant inhibitory effect. Copper released in the
synaptic cleft is bound bymetal-binding proteins, such as PrPC,
which binds copper with high affinity and sustains Cu(II) redox
cycling (5, 8, 24). In vitro results have shown that PrPC-bound
Cu(II) promotes NO oxidation and is consequently reduced to
Cu(I) (4). As PrPC-Cu is involved in glypican-1 heparan sulfate
S-nitrosylation (29), the complex may also have a role in
NMDAR S-nitrosylation.
Here, we show that PrPC exerts copper-dependent neuro-
protection by mediating NMDAR S-nitrosylation. We define
PrPC-Cu direct involvement in NMDAR S-nitrosylation com-
paring GluN2A and GluN1 S-nitrosylation levels in Prnp+ /+
and Prnp0/0 hippocampi and cultures treated with a copper
chelator. PrPC neuroprotective function is characterized com-
paring excitotoxicity susceptibility in different Prnp+ /+ and
Prnp0/0 hippocampal areas. The copper/NO-dependence of
PrPC neuroprotective activity is assessed observing the effects of
copper chelation, NOS inhibition, and NO donation on neuronal
death in wild-type and Prnp0/0 cultures.We propose amodel for
this molecular mechanism based on the results presented here.
Results
PrPC is involved in NMDAR S-nitrosylation
The S-nitrosylation of NMDAR extracellular cysteines may
be a mechanism by which the PrPC-Cu complex inhibits ion
gating. To test this hypothesis, wemeasuredGluN2A andGluN1
S-nitrosylation levels in adult Prnp+ /+ and Prnp0/0 hippocampi.
To compare wild-type with PrPC-null samples, the Western
blotting signals corresponding to each S-nitrosylated protein
(i.e.,GluN2A, GluN1 and b-Actin) were normalized against the
respective input signals. Then, the obtained GluN2A and GluN1
ratio values were normalized against the corresponding b-actin
ratio value, as an internal control. The resulting values for
Prnp+ /+ and Prnp0/0 hippocampi were compared by the Mann–
Whitney test. In PrPC-null hippocampus, we detected lower
GluN2A (n=9, p=0.0004) and GluN1 (n=9, p=0.00203) S-
nitrosylation levels compared with those in the wild type (Fig.
1A, B). These findings show that in PrPC-null hippocampus
NMDAR S-nitrosylation is reduced. We confirmed these results
by using an additional S-nitrosylation-detection method (Sup-
plementary Materials and Methods and Supplementary Fig.
S1; Supplementary Data are available online at www.liebert
pub.com/ars). This observation suggests that PrPC is involved in
GluN2A and GluN1 S-nitrosylation and, possibly through this
mechanism, it can modulate the NMDAR activity.
To exclude that the results observed in Prnp0/0 hippocampus
aredue todifferent levels of eitherGluN2A-containingNMDAR
or nNOS at synapses, we performed a co-immunoprecipitation
(coIP) with the postsynaptic density protein 95 (PSD95). The
results revealed comparable GluN2A (direct PSD95 inter-
actor), GluN1 (indirect PSD95 interactor), and nNOS levels in
Prnp+ /+ and Prnp0/0 hippocampal synapses (Supplementary
Materials and Methods and Supplementary Fig. S2A–C).
Furthermore, to exclude that the results observed in Prnp0/0
hippocampus are due to altered NOS activity, first, we as-
sessed the similarity of b-actin S-nitrosylation levels (Fig. 1A)
and then measured both the consumption of NADPH, an es-
sential cofactor for NO production, and the conversion of
radiolabeled arginine to radiolabeled citrulline (Supplementary
Materials and Methods). Adult Prnp+ /+ and Prnp0/0 samples
exhibited comparable kinetics for NADPH consumption and
the same capability to convert arginine to citrulline (Supple-
mentary Fig. S3A, C). Taken together, these results suggest
that the decreased NMDAR S-nitrosylation in PrPC-null hip-
pocampus is not due to a reduction in the levels of NMDAR
and nNOS at synapses or alterations in NO production.
In the absence of PrPC, hippocampal neurons
are more susceptible to NMDAR-mediated excitotoxicity
Since Prnp0/0 hippocampus shows lower NMDAR S-
nitrosylation (Fig. 1 and Supplementary Fig. S1) but the same
protein level at synapses (Supplementary Fig. S2A, C), PrPC-
null neurons should be more susceptible to excitotoxic treat-
ment. To investigate the neuroprotective role of PrPC through
glutamate receptor inhibition, we carried out excitotoxicity
studies on Prnp+ /+ and Prnp0/0 organotypic hippocampal
FIG. 1. In adult Prnp0/0 hippocampus, the S-nitrosylation
ofGluN2AandGluN1NMDARsubunits is lower compared
to wild type. (A) Signals of S-nitrosylated fraction, controls
without either biotin or ascorbate and corresponding input of
GluN2A, GluN1, and b-actin resulting from the biotin switch
assay of Prnp+ /+ and Prnp0/0 hippocampus; controls without
either biotin or ascorbatewere doneusingPrnp+ /+ samples. (B)
Statistical analysis ofS-nitrosylatedGluN2AandGluN1signals
normalized on the corresponding input and on b-actin; all error
bars indicate SD; **p< 0.01; ***p< 0.001. NMDAR, N-
methyl-d-aspartate receptors.
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cultures (OHC) by analyzing specifically neuronal death in
Cornus Ammonis 1 (CA1), Cornus Ammonis 3 (CA3), and
dentate gyrus (DG). We exposed Prnp+ /+ and Prnp0/0 OHC to
two toxic treatments withNMDAas selectiveNMDARagonist:
5lM NMDA for 3 h (prolonged insult) and 10lM NMDA for
10min (acute insult). We chose these two protocols after
observing that they induce low neuronal cell death levels in
wild-type samples, hence they can clearly reveal a different
susceptibility of Prnp0/0 samples. Neuronal cell death was
evaluated as pyknotic nuclei percentage over the total number of
nuclei in CA1, CA3, and DG, respectively. The concomitant
staining with the anti-neuronal nuclei marker antibody (NeuN)
allowed us to localize the pyknotic event in neurons and clearly
distinguished glia cells. Figure 2A–M shows the different
FIG. 2. Wild-type and PrPC-null OHC show different regional susceptibility to NMDA treatment, under both pro-
longed and acute insult. Images from three hippocampal regions are reported in rows: (A–D)CA1, (E–H)CA3, and (I–L)DG.
The four different combinations of treatment and samples are reported in columns: (A, E, I)Prnp + / + control, (B, F, J)Prnp + /+
treated with 5 lM NMDA for 3 h, (C, G, K) Prnp0/0 control, and (D, H, L) Prnp0/0 treated with 5 lM NMDA for 3 h. NeuN
staining is displayed in green and DAPI in red. Confocal microscope fluorescence images were acquired using a 40· /1.30 NA
oil objective. Comparison of the neuronal pyknotic nuclei percentage induced by 5 lMNMDA for 3 h (M; n = 4 OHC, 5 slices
per treatment in each culture) and by 10lMNMDA for 10min (N; n = 5OHC, 5 slices per treatment in each culture), calculated
over the total nuclei number, betweenPrnp + / + (white bars) andPrnp0/0 (black bars) OHC in CA1, CA3, and DG; all error bars
indicate SD; *p < 0.05, **p < 0.01. CA1,Cornus Ammonis 1; CA3,Cornus Ammonis 3; DAPI, 4¢,6-diamidino-2-phenylindole;
DG, dentate gyrus; OHC, organotypic hippocampal cultures. To see this illustration in color, the reader is referred to the web
version of this article at www.liebertpub.com/ars
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responses of Prnp+ /+ and Prnp0/0 OHC to the prolonged
treatment (n=4 OHC, 5 slices per treatment in each culture). In
CA1, the NMDA exposure significantly induced neuronal cell
death in both Prnp+ /+ ( p=0.03038) and Prnp0/0 (p=0.03038)
OHC (Fig. 2A–D, M), but at the same time, it revealed a higher
susceptibility of Prnp0/0 OHC ( p= 0.03038). The NMDA
treatment did not induce significant neuronal cell death in
wild-type CA3 and DG, whereas it yielded high toxicity for
both regions in PrPC-null cultures (CA3, p = 0.03038; DG,
p = 0.03038), highlighting a significant difference between
Prnp + / + and Prnp0/0 (CA3, p = 0.03038; DG, p = 0.01996)
(Fig. 2E–M). The same quantitative differences between
Prnp + / + and Prnp0/0 OHC were observed following the
acute treatment (Fig. 2N; n = 5 OHC, 5 slices per treat-
ment in each culture). In CA1, 10 lM NMDA for 10 min
induced neuronal cell death in both Prnp + / + ( p =
0.01996) and Prnp0/0 ( p = 0.01996) OHC, but it revealed
a higher susceptibility of Prnp0/0 compared with Prnp + / +
( p = 0.02157). In CA3, the acute treatment was toxic only
for Prnp0/0 OHC ( p = 0.03038), confirming their higher
susceptibility compared with Prnp + / + ( p = 0.01421). The
wild-type DG showed low levels of neuronal cell death in
response to the acute insult ( p = 0.02518), whereas the
same treatment caused a greater cell death percentage
( p = 0.01421) in Prnp0/0 DG, leading to a higher damage
compared to Prnp + / + ( p = 0.00507). The enhanced sus-
ceptibility of Prnp0/0 neurons to the excitotoxic stimulus
confirms findings previously reported in the literature,
obtained by stimulating neurons with kainate (34) and
NMDA (21).
To evaluate the early changes in neuronal cell viability, the
MTT (thiazolyl blue tetrazolium bromide) mitochondrial
toxicity assay was performed on Prnp + / + and Prnp0/0 OHC
after exposure to 5 lM NMDA for 3 h. Results revealed that
Prnp0/0 OHC are more susceptible to excitotoxicity also in
the early phases after insult (Supplementary Materials and
Methods and Supplementary Fig. S4).
The excitotoxic mechanism induced by NMDAR over-
activation is triggered by calcium ion influx into the neuronal
cell (10). To verify that the excitotoxicity observed was a
calcium-mediated effect, the same treatments were per-
formed adding a calcium chelator, ethylene glycol tetraacetic
acid (EGTA; n = 3 OHC, 4 slices per treatment in each cul-
ture). It should be noted that the treatment with 5 lM NMDA
was shortened to 1.5 h since calcium deprivation for 3 h re-
sulted to be toxic per se. As expected, adding EGTA to
NMDA abolished neuronal cell death in all the analyzed re-
gions and under both prolonged and acute insults (Fig. 3A–C
and Supplementary Fig. S5A–I; Prnp + /+ CA1: p = 0.03038
and p = 0.03038; Prnp0/0 CA1: p = 0.01996 and p = 0.03038;
Prnp0/0 CA3: p= 0.01894 and p = 0.0294; Prnp0/0 DG:
p = 0.01945 and p = 0.01996). Shortening the exposure time
FIG. 3. Neuronal cell death in-
duced by NMDA treatment is pre-
vented by calcium chelation and
NMDAR antagonist, unaltered by
AMPA/kainate receptor and
GluN2B-containing NMDAR an-
tagonists. Comparison of NMDA-
induced neuronal pyknotic nuclei
percentages between EGTA-trea-
ted Prnp + /+ and Prnp0/0 OHC in
the (A) CA1, (B) CA3, and (C)
DG; n = 3 OHC, 5 slices per treat-
ment in each culture. Comparison of
NMDA-induced neuronal pyknotic
nuclei percentages between
NMDAR inhibitors (AP5 and/or
CNQX)-treated Prnp + /+
and Prnp0/0 OHC in the (D) CA1,
(E) CA3, and (F) DG; n = 4 OHC,
5 slices per treatment in each cul-
ture. ComparisonofNMDA-induced
neuronal pyknotic nuclei percentages
between GluN2B inhibitor (ifenpro-
dil)-treated Prnp+ /+ and Prnp0/0
OHC in the (G) CA1, (H) CA3, and
(I) DG; n=4 OHC, 5 slices per
treatment in each culture. All error
bars indicate SD; *p<0.05. AMPA,
a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid;AP5, (2R)-
amino-5-phosphonovaleric acid;
CNQX, 6-cyano-7-nitroquinoxa-
line-2,3-dione; EGTA, ethylene
glycol tetraacetic acid. To see this
illustration in color, the reader is
referred to the web version of this
article at www.liebertpub.com/ars
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to 5 lM NMDA did not affect the differences between
Prnp + /+ and Prnp0/0 OHC.
Next, we assessed the primary involvement of NMDAR in
the neurotoxic mechanism (n= 4 OHC, 5 slices per treatment
in each culture). Adding the NMDAR blocker AP5 to 5 lM
NMDA for 3 h abolished cell death (Fig. 3D–F and Supple-
mentary Fig. S6A–F; Prnp + /+ CA1: p= 0.03038; Prnp0/0
CA1: p = 0.03038; Prnp0/0 CA3: p= 0.03038; Prnp0/0 DG:
p = 0.03038). In contrast, adding the a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)/kainate receptor
blocker 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) to
5 lM NMDA for 3 h did not diminish cell death in Prnp + /+
CA1, Prnp0/0 CA1, and Prnp0/0 CA3 (Fig. 3D, E and Sup-
plementary Fig. S6A–D). However, adding CNQX to NMDA
did reduce the pyknosis percentage inPrnp0/0 DG (p=0.03038),
suggesting a partial AMPA/kainate receptor involvement
(Fig. 3F and Supplementary Fig. S6E, F). Overall, despite the
AMPA/kainate receptor inhibition, the higher cell death
levels in PrPC-null were maintained, confirming a primary
involvement of NMDAR. To assess whether the neurotoxic
effect was mainly due to either GluN2A- or GluN2B-
containig NMDAR, we used ifenprodil, a selective inhibitor
of GluN2B. The excitotoxic condition applied was 10 lM
NMDA for 10min since ifenprodil has an aspecific toxic
effect if added to lower NMDA concentrations (20). In both
Prnp + /+ and Prnp0/0 OHC, ifenprodil did not reduce the cell
death levels observed with NMDA alone, suggesting that the
overactivation of GluN2B-containing receptor is not the
leading cause for neuronal death (Fig. 3G–I and Supple-
mentary Fig. S7). A major involvement of GluN2A-
containing receptor is therefore a more likely hypothesis.
Copper ions are required for PrPC
to support NMDAR S-nitrosylation
Copper ions are fundamental in the S-nitrosylation reac-
tion because their reduction from Cu(II) to Cu(I) allows for
the oxidation of NO and its ensuing reaction with cysteine
thiols (11, 17). Because PrPC-bound Cu(II) promotes NO
oxidation (4), PrPC is likely to promote NMDAR S-
nitrosylation through the copper ions it binds. To verify this
mechanism, we measured GluN2A and GluN1 S-nitrosylation
levels in Prnp+ /+ and Prnp0/0 OHC upon treatment with cu-
prizone (CZ), a selective copper chelator that binds Cu2+ .
Since Cu2+ promotes S-nitrosylation while Cu+ triggers de-
nitrosylation, CZ treatment specifically blocks S-nitrosylation
induction. CZ does not affect neuronal viability and
cannot cross plasma membranes (2); hence, it should not af-
fect cytoplasmic protein S-nitrosylation. Indeed, b-actin S-
nitrosylation levels were comparable among control and CZ-
treated wild-type and PrPC-null OHC, providing us with a
reliable internal control for the normalization of NMDAR S-
nitrosylation signal. Moreover, we used serum-free medium to
avoid copper content variability and thereby ensure uniform
copper chelation. In serum-freemedium, CZ binds copper ions
released in the synaptic cleft (36), thus affecting the copper-
mediated S-nitrosylation in the extracellular environment.
Prnp+ /+ and Prnp0/0 OHC were exposed to 20lM CZ for 3 h,
immediately frozen, and then processed for the detection of S-
nitrosylated proteins. As already observed in the hippocampus,
GluN2A and GluN1 S-nitrosylation was decreased in Prnp0/0
samples (Fig. 4A, B; n = 4 slice pools, p = 0.03038 and
p = 0.03038, respectively). Consistent with the hypothesized
mechanism, CZ addition reduced GluN2A and GluN1 S-
nitrosylation in Prnp+ /+ OHC ( p= 0.03038 and p= 0.03038,
respectively) but not inPrnp0/0 ones (Fig. 4A, B). Furthermore,
NMDAR S-nitrosylation levels in CZ-treated wild-type OHC
were not different from either control or CZ-treated Prnp0/0
samples. This result shows that CZ addition affects NMDARS-
nitrosylation only inwild type but not inPrnp0/0 OHC; hence, it
strongly suggests that the lower S-nitrosylation of NMDAR
subunits in Prnp0/0 samples is due to the lack of the PrPC-Cu
complex and that PrPC-bound copper ions favor the S-
nitrosylation of NMDAR. Residual GluN1 and GluN2A S-
nitrosylation is due to PrPC-independent mechanisms.
To rule out that the results observed inPrnp0/0 OHC are due
to different levels of GluN2A-containing NMDAR and nNOS
at synapses, we performed coIP assays with PSD95 using
hippocampi from postnatal day 20 (P20) mice. This age was
selected because it is close to the developmental stage of OHC
FIG. 4. Copper chelation de-
creases S-nitrosylation of GluN2A
and GluN1 in wild type but not in
Prnp0/0 OHC. (A) Signals of S-
nitrosylated fraction and corre-
sponding input of GluN2A, GluN1,
and b-actin resulting from the biotin
switch assay of Prnp+ /+ and Prnp0/0
OHC, treated and untreated with CZ;
adult wild-type hippocampus was
used as negative (- biotin) and posi-
tive control. (B)Statistical analysis of
S-nitrosylated GluN2A and GluN1
signals normalized on the corre-
sponding input and on b-actin; all
error bars indicate SD; sample size
n= 4; *p< 0.05, n.s., not statistically
significant difference. CZ, cuprizone.
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at the time of the treatment. The results revealed comparable
GluN2A,GluN1, and nNOS levels in P20Prnp+ /+ andPrnp0/0
hippocampal synapses (Supplementary Fig. S8A–C). Also, at
this developmental stage, we reasoned to exclude that the
results observed in Prnp0/0 OHC were due to different levels
of NOS activity. Like in the adult hippocampus, we observed
that b-actin S-nitrosylation levels were similar in control and
CZ-treated Prnp + /+ and Prnp0/0 OHC (Fig. 4A). Next, we
measured the consumption of NADPH and the conversion of
radiolabeled arginine to radiolabeled citrulline in P20 sam-
ples and found comparable results in Prnp + /+ and Prnp0/0
hippocampi (Supplementary Fig. S3B, C).
The neuroprotective function of PrPC
is copper-dependent
So far, we have shown that in Prnp0/0 mouse OHC,
NMDAR S-nitrosylation is not mediated by copper since it is
not lowered by CZ addition. However, CZ treatment de-
creases NMDAR S-nitrosylation in Prnp + / + mouse OHC to
the level detected in Prnp0/0 mouse OHC (Fig. 4). Since
extracellular cysteine S-nitrosylation inhibits NMDAR by
lowering the frequency of channel opening (23), we mea-
sured intracellular calcium [Ca2 + ]i waves in wild-type mouse
hippocampal neurons upon treatment with 20lM CZ, 5lM
NMDA, and 5lM NMDA + 20lM CZ (Supplementary
Materials and Methods). We found that both CZ and NMDA
triggered [Ca2 + ]i waves, but the addition of CZ to NMDA
induced a much higher [Ca2 + ]i increase (Supplementary Fig.
S9). These results indicate that copper chelation enhances
NMDAR channel opening. Consistent with this finding, it has
been reported that, upon copper chelation, wild-type hippo-
campal neurons exhibit nondesensitizing NMDAR currents
comparable to those registered in Prnp0/0 (40). Therefore, we
studied the neurotoxic effects of NMDA exposure in Prnp+ /+
and Prnp0/0 OHC in the presence of CZ (n= 4 OHC, 5 slices
per treatment in each culture). CZ treatment without NMDA
did not induce neuronal cell death in neither Prnp + / + nor
Prnp0/0 OHC (Supplementary Fig. S10A–F). Our results
confirm the neuroprotective function of PrPC through a
copper-dependent inhibition of NMDAR (Fig. 5). In
wild-type OHC CA1, copper chelation did not enhance sig-
nificantly the pyknosis, but it abolished the difference with
PrPC-null OHC CA1 (Fig. 5A, G). In wild-type OHC CA3
and DG, CZ addition to NMDA significantly increased
neuronal cell death (Fig. 5C, E, H, I; p = 0.01219, p=
0.02157). In contrast, in Prnp0/0 CA1 and DG, the copper
chelator did not alter the susceptibility of neurons to NMDA
(Fig. 5 B, F, G, I), whereas in Prnp0/0 CA3, it did decrease
neuronal cell death (Fig. 5D, H; p = 0.01219). This partial
neuroprotection exerted by CZ inPrnp0/0 CA3may be related
to a toxic effect triggered by copper ions released after
NMDAR activation in the absence of PrPC. These results
indicate that copper is neuroprotective in wild-type mouse
OHC; on the contrary, this effect is greatly reduced in PrPC-
null OHC, thus suggesting that PrPC and copper can con-
tribute to neuroprotection only if simultaneously present.
The neuroprotective function of PrPC is NO-dependent
Next, we verified the involvement of NO in PrPC neuro-
protective function. To this aim, we studied the neurotoxic
effect of NMDA exposure in Prnp + / + and Prnp0/0 OHC
in the presence of either Nx-nitro-l-arginine (NNA), which
blocks NO production by all NO synthase isoforms
(i.e., nNOS, endothelial NOS, and inducible NOS) or S-
nitrosoglutathione (GSNO), a NO donor (n= 4 OHC, 5 slices
per treatment in each culture). Both NNA and GSNO had no
toxic effect (Supplementary Fig. S10A–F). NOS inhibition by
NNA significantly enhanced cell death in all the analyzed re-
gions in wild-type hippocampal cultures (Fig. 6A, C, E, G–I;
p= 0.03038, p= 0.03038, p= 0.03038), while it had no effect in
PrPC-null OHC (Fig. 6B, D, F, G–I). GSNO addition to
NMDA significantly increased neuronal cell survival in all the
analyzed regions in PrPC-null OHC (Fig. 6B, D, F, G–I;
p= 0.01996, p= 0.03038, p= 0.03038) and also in wild-type
CA1 region (Fig. 6A, G; p= 0.03038).
These results indicate that NOS production of NO is nec-
essary to mediate PrPC neuroprotective function.
Discussion
Determining the function of PrPC is of utmost importance
to understand different neurodegeneration mechanisms, in
particular those underlying prion disorders and Alzheimer
disease (AD). In prion disorders, the loss of PrPC function
upon protein aggregation may contribute to the pathology
progression (1). PrPC has been found to play a role also in AD
(19), where it has been involved in pathological mechanisms
together with copper and NMDAR. Recent results indicate
that the interaction with Ab oligomers prevents the PrPC-Cu
complex-mediated inhibition of NMDAR, leading to over-
activation of the ion channel (40). Zamponi and colleagues
propose that PrPC bound to copper limits excessive NMDAR
activity by reducing the receptor affinity for glycine. In the
present work, we put forward an additional mechanism in
which PrPC-Cu modulates NMDAR together with NO. The
novelty of this study is represented by the description of the
functional interaction of PrPC, copper, and NO. The rele-
vance of copper, NO, and NMDAR overactivation in pro-
cesses that lead to synapse loss in AD is widely accepted (15).
In light of these premises, the mechanism we present here
may help our understanding of the pathological processes
involved in the progression of both AD and prion disorders.
Here, we argue that PrPC protects glutamatergic synapses
from excitotoxic insults by promoting NMDAR S-nitrosylation.
Figure 7 shows the proposed model for NMDAR inhibition by
PrPC. Glutamate released from the presynaptic terminal acti-
vates NMDAR with ensuing calcium influx. In the intracellular
compartment, calcium binds to CaM, and the Ca2+ /CaM com-
plex activates, among others, nNOS andAtp7a (22, 36); NO and
copper are thus released in the synaptic cleft. Because of PrPC
high affinity to copper ions (8) and high expression levels in
hippocampal synapses (31, 35), it is likely to bind copper re-
leased in the synaptic cleft. In thismilieu, PrPC-boundCu(II) can
oxidize NO to NO+ and be reduced to Cu(I) (4). This reaction
enables the electrophilic attack of NO+ on GluN2A and GluN1
extracellular cysteine thiol groups, resulting in the S-nitrosyla-
tion of NMDAR. coIP experiments of PrPC with NMDAR
subunits have yielded positive results (40), confirming the
proximity of PrPC and NMDAR subunits in lipid rafts (9, 32).
The experimental evidence we present here supports this mo-
lecular mechanism.
NMDAR regulation operated by NO reduces significantly
the neurotoxic effect induced by the overactivation of the
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NMDAR-coupled ionic channel and the ensuing excessive
calcium entry (30). S-nitrosylation diminishes the amplitude
of NMDAR-evoked currents by reducing the number of
channel openings (23). By comparing GluN2A and GluN1
S-nitrosylation levels in wild-type and PrPC-null mouse
hippocampi, we found that, in absence of PrPC, NMDAR S-
nitrosylation levels are decreased. S-nitrosylation can proceed
through different routes not involving copper (14), and PrPC-
Cu is not the only complex able to support the copper-mediated
reaction; otherwise, no S-nitrosylated NMDAR signal would
be detectable in PrPC-null samples. However, the extent of the
reduction observed is remarkable, indicating that PrPC-Cu is a
key player in this post-translational modification on NMDAR.
Since S-nitrosylation limits NMDAR overactivation, thus
staving off apoptosis, PrPC-null neurons should be more
susceptible to excitotoxicity. Consistent with this observation
and with results reported in the literature (21), we found that
PrPC ablation strongly impairs neuronal survival upon toxic
exposure to NMDA. By applying a pool of glutamate recep-
tors antagonists, we found that GluN2A-containing NMDAR
FIG. 5. Copper chelation
increases neuronal cell
death in Prnp1/1 OHC but
not in Prnp0/0. Images from
Prnp + /+ and Prnp0/0 OHC
areas are reported in rows:
(A) Prnp + / + CA1; (B)
Prnp0/0 CA1; (C) Prnp + /+
CA3; (D) Prnp0/0 CA3; (E)
Prnp + /+ DG; (F) Prnp0/0
DG. The different treatments
are reported in columns:
5 lM NMDA for 3 h, left
column; 5 lM NMDA + 20
lM CZ for 3 h, right column.
NeuN staining is displayed in
green and DAPI in red.
Confocal microscope fluo-
rescence images were ac-
quired using a 40 · /1.30 NA
oil objective. Graphs show
the comparison of the neu-
ronal pyknotic nuclei per-
centage, calculated over the
total nuclei number, between
Prnp + /+ and Prnp0/0 OHC in
CA1 (G), CA3 (H), and DG
(I); all error bars indicate
SD; sample size n = 4 OHC,
5 slices per treatment in each
culture; *p < 0.05, **p < 0.01.
To see this illustration in
color, the reader is referred to
the web version of this article
at www.liebertpub.com/ars
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were mainly responsible for increasing the cell death level in
PrPC-null neurons. These results contrast with the notion that
GluN2B-enriched extrasynaptic receptors may be key medi-
ators of neuron death (16). However, growing evidence sup-
ports an involvement of both GluN2A and GluN2B in
synaptic and extrasynaptic NMDAR-mediated excitotoxicity
(39, 41, 42). Therefore, it is plausible that a dysfunction in
GluN2A inhibition causes higher neuron death in PrPC-null
mouse OHC. Interestingly, GluN2A is the subunit containing
the cysteine residue that mediates the predominant inhibitory
effect of NO (7, 23). This regulation provides a clear link
between the increased neuron death level and the lower
NMDAR S-nitrosylation detected in PrPC-null mouse hip-
pocampus. In situ hybridization experiments have shown that
PrPC knockout mouse hippocampus has higher GluN2A
mRNA levels (27). However, we excluded the possibility that
the higher susceptibility of PrPC-null mouse OHC was due to
an overexpression of NMDAR at synapses, as we revealed
comparable levels of interaction between PSD95 and Glu-
N2A, and indirectly with GluN1, in wild-type and PrPC-null
mouse hippocampi.
By measuring GluN2A and GluN1 S-nitrosylation levels
in CZ-treated wild-type and PrPC-null mouse OHC by CZ
addition, we found that copper chelation lowers GluN2A and
GluN1 S-nitrosylation in wild-type cultures but not in PrPC-
null ones. The residual signal detected in wild-type upon
copper deprivation was not different from that in treated and
untreated PrPC knockout cultures.
In line with previously published electrophysiological re-
cordings of NMDAR currents (40), our results on S-
nitrosylation highlight that PrPC regulation of NMDAR
activity is copper dependent. Consistent with this fact, we
found that also the neuroprotective effect of PrPC requires
copper. These results convincingly indicate that in glutama-
tergic synapses, the neuroprotective action of PrPC depends
on copper ions and that, vice versa, the neuroprotective action
FIG. 6. NOS inhibition in-
creases neuronal cell death in
Prnp1/1 OHC but not in
Prnp0/0, while NO addition
enhances neuron survival
upon NMDA exposure. Ima-
ges from Prnp+ /+ and Prnp0/0
OHC areas are reported in
rows: (A) Prnp+ /+ CA1; (B)
Prnp0/0 CA1; (C) Prnp+ /+
CA3; (D) Prnp0/0 CA3; (E)
Prnp+ /+ DG; (F) Prnp0/0
DG. The different treatments
are reported in columns: 5lM
NMDA for 3 h, left column;
5lMNMDA+ 1mMNNA for
3 h, central column; 5lM
NMDA+20lMGSNOfor3 h,
right column. NeuN staining is
displayed in green and DAPI
in red. Confocal microscope
fluorescence images were ac-
quired using a 40· /1.30 NA
oil objective. Graphs show the
comparison of the neuronal
pyknotic nuclei percentage,
calculated over the total nuclei
number, between Prnp+ /+ and
Prnp0/0 OHC in CA1 (G), CA3
(H), and DG (I); all error bars
indicate SD; sample size n= 4
OHC, 5 slices per treatment in
each culture; *p<0.05. GSNO,
S-nitrosoglutathione; NNA,
Nx-nitro-L-arginine; NO, ni-
tric oxide. To see this illustra-
tion in color, the reader is
referred to the web version of
this article at www.liebertpub
.com/ars
PRPC-BOUND CU MEDIATES NMDAR S-NITROSYLATION 779
of copper relies on PrPC expression. This finding has relevant
implications in defining copper-mediated modulation of
NMDAR and the involvement of copper in neuroprotection,
as these functions are impaired in both AD and prion dis-
eases. Moreover, it is known that copper metabolism dys-
function is a primary cause of other pathologies, such as
Menkes’ disease (MD)—a disorder caused by a loss-of-
function mutation in the Atp7a-encoding gene that results in
altered copper trafficking (26). Indeed, hippocampal neurons
derived from a MD murine model have shown altered
NMDAR current and increased damage upon excitotoxic
stimulus (37). Strikingly, this phenotype is very similar to
that observed in PrPC-null models (21, 34, 38).
Our findings indicate that PrPC, copper, and NO regulate
NMDAR and impart neuroprotection through a common
mechanism that is likely to be lost in AD, MD, and prion
diseases, thus leading to synapse degeneration. In this mech-
anism, PrPC-bound copper ions act as electron acceptors in the
reaction between NO and NMDAR cysteine thiols. The ensu-
ing S-nitrosylation inhibits the receptor and reduces the neu-
rotoxic effect caused by its overactivation. This mechanism is
neuroprotective and crucial for normal synaptic functionality.
As in the case of NMDAR, PrPC-Cu may also promote the
S-nitrosylation of other membrane proteins. Indeed, inducing
protein S-nitrosylation may be an overarching function of
PrPC. The novel mechanism presented here may provide a
platform to investigate additional and previously unforeseen
cellular processes in which PrPC may be involved.
Materials and Methods
Animals
All experiments were performed in accordance with Eu-
ropean regulations (European Community Council Directive,
November 24, 1986 [86/609/EEC]). Experimental proce-
dures were notified to and approved by the Italian Ministry of
Health, Directorate General for Animal Health. All experi-
ments were approved by the local authority veterinary service
of Trieste, Italy, and by the Ethics Committee of the Scuola
Internazionale Superiore di Studi Avanzati (SISSA), Trieste.
All efforts were made to minimize animal suffering and to
reduce the number of animals used. Inbred FVB/N (Friend
virus B-type susceptibility-NIH) wild-type and FVB Prnp0/0
mice were used in these experiments. The FVB Prnp0/0 mice
were obtained from George A. Carlson, McLaughlin Re-
search Institute (Great Falls, MT) and were bred by back-
crossing with the original Prnp0/0 mice at least 20 times (25).
S-nitrosylated protein detection: biotin switch assay
The biotin switch assay was performed, as described by
Jaffrey and Snyder (18) with a few modifications. Mouse
FIG. 7. Mechanism of PrPC-mediated S-nitrosylation of NMDAR. Glutamate released from the presynaptic terminal
activates NMDAR on the postsynaptic terminal. NMDAR activation triggers Na + and Ca2 + influx, together with K+ efflux.
In the intracellular compartment, Ca2 + ions bind different proteins, including calmodulin (CaM). The Ca2 + /CaM complex
activates, among others, neuronal nitric oxide synthase (nNOS) and copper-transporting ATPase 1 (Atp7a): nNOS acti-
vation results in NO release in the synaptic cleft; Atp7a activation in the trans-Golgi network (TGN) results in Cu2 + release
in the synaptic cleft. Released Cu2 + ions are immediately bound by copper-binding proteins: PrPC is highly expressed in
both presynaptic and postsynaptic terminals, and it can be included in lipid raft domains that also contain NMDARs, and it
has high affintiy for both Cu2 + and Cu + . Released NO can react with extracellular cysteines thiols of NMDAR subunits
GluN1 and GluN2A, leading to cysteines S-nitrosylation (SNO-Cys). The S-nitrosylation inhibits NMDAR activation by
closing the channel. The chemical reaction between NO and the cystein thiol requires the presence of an electron acceptor,
often represented by Cu2 + . According to this model, PrPC brings the Cu2 + ions that support the reaction of NO with thiols,
leading to the S-nitrosylation of GluN1 and GluN2A, thus inhibiting NMDAR. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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hippocampal samples (age-matched samples from 6-, 10-,
and 12-month-old male animals) were dissected, immedi-
ately frozen in liquid nitrogen, and stored at - 80C. Each
hippocampus was homogenized in 400 ll HEN buffer:
250mM HEPES pH 7.5 (H3375; Sigma-Aldrich, St Louis,
MO), 1mM EDTA (E6758; Sigma-Aldrich), 0.1mM neo-
cuproine (N1501; Sigma-Aldrich), protease inhibitors cock-
tail (Roche Diagnostics Corp., Mannheim, Germany), and
centrifuged at 2000 g, 10min at 4C. To evaluate the role of
copper in NMDAR S-nitrosylation, Prnp+ /+ and Prnp0/0 OHC
were treated for 3 h with 20lM CZ (14690; Sigma-Aldrich)
from the 4mM stock in 50% ethanol, then immediately frozen.
For each experiment, at least 60 slices per group were collected
and homogenized in 100ll HEN buffer by sonication. Protein
concentration in the supernatant was determined by bicincho-
ninic acid assay and the same amount of proteins per sample
was used for the further steps of the protocol (1mg for hip-
pocampal samples and 0.7–1mg for OHC depending on the
lowest sample concentration in each experiment). All the re-
agents were used proportionally. Samples were diluted to
0.8lg/ll in HEN buffer+ 0.04% CHAPS (C9426; Sigma-
Aldrich) and incubated at 50C for 1 h in 4 volumes of blocking
solution: 9 volumes of HEN, 1 volume of 25% w/v SDS
(L3771; Sigma-Aldrich) in ddH2O, and 20mM S-methyl
thiomethanesulfonate (64306; Sigma-Aldrich) from the 2 M
stock solution in dimethylformamide. S-methyl thiomethane-
sulfonate was removed by acetone precipitation and the protein
pellet was resuspended in 100ll of HENS buffer (HEN+ 1%
SDS) per mg of starting proteins. To selectively and effi-
ciently reduce S-nitrosylated thiols, ascorbate (A4034; Sigma-
Aldrich), prepared as 180mM in ddH2O, was added to 30mM
final concentration in the samples, and the reaction was carried
out for 3 h at 25C (14). A negative control without ascorbate
was performed on Prnp+ /+ samples to check the efficiency of
thiols blockingwith S-methyl thiomethanesulfonate. Ascorbate
was removed by acetone precipitation and the protein pellet
was resuspended in 100ll of HENS buffer per mg of starting
proteins. EZ-Link HPDP-biotin (21341; Thermoscientific,
Waltham, MA) was used to bind free thiols, corresponding to
the previously S-nitrosylated residues. It was added 1:3 to the
samples from the 4mM stock in dimethylformamide. A neg-
ative control without biotin was performed on Prnp+ /+ sam-
ples to check the selective binding to the resin. After 1 h
incubation at 25C, HPDP-biotin was removed by dialysis in
HENS buffer. To purify biotinylated proteins, 2 volumes of
neutralization buffer (20mM HEPES pH 7.5, 100mM NaCl,
1mM EDTA, 0.5% Triton X-100 [X100; Sigma-Aldrich]) and
50ll of wet Immobilized NeutrAvidin Agarose (29200;
Thermoscientific) were added to the samples and incubated for
2 h at room temperature (RT). Resin was washed 5 times with
neutralization buffer adjusted to 600mM NaCl; biotinylated
proteins were eluted directly in SDS-PAGE sample buffer,
boiled, and processed for Western blot detection. For each
sample, 30lg of protein extract were loaded as input. The
following primary antibodies were used: anti-GluN1 1:500–
1:2000 (G8913; Sigma-Aldrich); anti-GluN2A 1:500–1:2000
(G9038; Sigma-Aldrich); monoclonal anti-PrP SHA31 1lg/
ml (A03213; BertinPharma,Montigny le Bretonneux, France);
anti-b-actin Peroxidase (AC-15) 1:10,000 (A3854; Sigma-
Aldrich). After incubation with the secondary antibody,
membranes were developed with the ECL detection reagent
(GE Healthcare, Waukesha, WI) and recorded by the digital
imaging system Alliance 4.7 (UVITEC, Cambridge, United
Kingdom). Band quantification was performed with Uviband
15.0 software (UVITEC) obtaining an optical density (OD)
value. To normalize OD values, the following formula was
applied: (NMDAR subunit S-nitrosylation/input)/(b-actin S-
nitrosylation/input). Basically, S-nitrosylation signals were
normalized on the corresponding input. Then, NMDAR sub-
unit values were normalized on b-actin value. Prnp+ /+ and
Prnp0/0 samples were compared by the Mann–Whitney test
setting F(x)< >G(x) as alternate hypothesis.
Organotypic hippocampal cultures
preparation and treatments
OHC preparation protocol was set up based on Gahwiler’s
protocol (13). Briefly, in aseptic condition, P5 mouse hip-
pocampus was dissected in the dissection medium (Gey’s
balanced salt solution, 5.6mM d-glucose [G8270; Sigma-
Aldrich], 1mM kynurenic acid [K3375; Sigma-Aldrich]) and
sliced by means of a tissue chopper into 300-lm-thick sec-
tions. After washing in the dissection medium for 40min at
4C, slices showing an intact hippocampal cytoarchitecture
were selected, singularly attached to a coverslip by embed-
ding in a chicken plasma (P3266; Sigma-Aldrich) and
thrombin clot (112374; Merck KGaA, Darmstadt, Germany)
and maintained at 10 rotations per hour at 37C in Nunc cell
culture tubes (156758; Thermoscientific) with a medium
composed of 50% basal medium Eagle (41010026; Gibco,
Carlsbad, CA), 25% horse serum (26050-088; Gibco), 25%
Hank’s balanced salt solution (24020141; Gibco), 5.6mM d-
glucose, 2mM l-glutamine (25030-032; Gibco). After 13
days in vitro, OHCwere treated in the serum-free medium, as
described in Supplementary Table S1. The drug stock solu-
tions were prepared as follows: 1mM NMDA (0114; Tocris
Biosciences, Missouri, United Kingdom) in ddH2O stored at
- 20C; 250mM EGTA (E4378; Sigma-Aldrich) in phos-
phate-buffered saline (PBS), pH 7.4, stored at RT; 40mM
CNQX (C239; Sigma-Aldrich) in dimethyl sulfoxide
(DMSO, D8418; Sigma-Aldrich) stored at - 20C; 10mM
(2R)-amino-5-phosphonovaleric acid (AP5, A5282; Sigma-
Aldrich) in ddH2O stored at - 20C; 5mM threo ifenprodil
hemitartrate (2892; Tocris Biosciences) in ddH2O stored at -
20C; 10mM GSNO (N4148; Sigma-Aldrich) in ddH2O
stored at - 20C; freshly prepared three NNA (N5501; Sig-
ma-Aldrich) in serum-free medium; freshly prepared 4mM
CZ in 50% ethanol. To induce excitotoxicity, OHC were
exposed either to 5 lMNMDA for 3 h or to 10 lMNMDA for
10min. Experiments with EGTA were performed using
2mM EGTA in combination with either 5 lM NMDA for
1.5 h (EGTA treatment for 3 h was toxic for OHC) or 10 lM
NMDA for 10min. Treatments with 5lM NMDA in com-
bination with either 50lM AP5 or 20 lM CNQX or 20 lM
GSNO or 1mMNNA or 20 lMCZwere incubated for 3 h. To
obtain a more complete inhibition, AP5, CNQX, and NNA
were preincubated for 30min before adding NMDA. Treat-
ments with NMDA and ifenprodil were carried out differ-
ently because of the toxic effect of ifenprodil when associated
to low NMDA concentrations (20). For this reason, OHC
were exposed to 10lM NMDA and 3 lM ifenprodil for
10min. To evaluate neuronal cell death, all the described
treatments were followed by a 24 h washout before proces-
sing OHC for immunofluorescence.
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Immunofluorescence
To evaluate neuronal cell death, slices were fixed in 4%
paraformaldehyde (P6148; Sigma-Aldrich) in PBS, pH 7.4,
O/N at 4C. To improve the nuclear staining, slices were
treated as follows: 3 · 5min washes in PBS with 1% Triton
X-100, 10min in 0.1N HCl at 4C, 10min in 0.2N HCl at
RT, 20min in 0.2N HCl at 37C, 12min in borate buffer pH
8.4 at RT, 3 · 5min washes in PBS with 1% Triton X-100.
Slices were incubated for 2 h at RT in the blocking solution
(1M glycin [G8898; Sigma-Aldrich], 5% normal goat serum
[005-000-121; Jackson ImmunoResearch] in PBS with 1%
Triton X-100) and O/N at 4Cwith anti-neuronal nuclei (NeuN)
cloneA60 antibody 1:500 (mab377;Millipore, Billerica,MA) in
the blocking solution. Afterwashingwith PBS and 1%TritonX-
100, slices were incubated with Alexa fluorophore-conjugated
secondary antibodies (1:500, R37120; Invitrogen, Carlsbad,
CA) and 4¢,6-diamidino-2-phenylindole (DAPI, 1:500) in the
blocking solution for 2 h at RT. Slices were washed in PBS,
rinsed in water, and mounted with VectaShield (Vector La-
boratories, Burlingame, CA).
Confocal microscopy, image analysis,
and statistics of OHC experiments
Immunofluorescence images were acquired on a Leica
DMIRE2 confocal microscope (Leica Microsystem GmbH,
Wetzlar, Germany) equipped with DIC and fluorescent op-
tics, diode laser 405 nm, and Ar/ArKr 488 nm lasers. The
fluorescence images (1024 · 1024 pixels) were acquired with
a 40 · /1.30 NA oil objective, additionally zoomed 1.5-fold,
with 200Hz acquisition speed. Stacks of z-sections with an
interval of 3 lm were sequentially scanned. CA1, CA3, and
DG were the regions selected for the analysis. A protocol
for automatic count of the total amount of nuclei was set up
for each hippocampal zone with the Volocity 5.4 3D imaging
software (PerkinElmer, Coventry, United Kingdom). The
same software was used to manually count the pyknotic nu-
clei. The dead cell count was performed as a blind analysis.
The CA1, CA3, and DG regions were clearly distinguishable
in OHC used in these experiments (Supplementary Fig.
S11A) and the staining protocol allowed for the exact iden-
tification of neuronal pyknotic nuclei (Supplementary Fig.
S11B). Pyknotic nuclei count results for Prnp + / + and Prnp0/0
OHC were compared by performing the Mann–Whitney test
setting F(x) < >G(x) as alternate hypothesis. Each culture
preparation (resulting from three to four mice dissection) was
considered as one sample (n = 1). In each culture, the average
pyknotic nuclei percentage among the hippocampal slices
(four to five slices) of the same treatment group was calcu-
lated, grouped with values obtained from other OHC of the
same genotype with the same treatment for a final sample size
of four (n= 4) and compared with the other treatments and
genotype by means of the Mann–Whitney test.
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Abbreviations Used
AD¼Alzheimer disease
AP5¼ (2R)-amino-5-phosphonovaleric acid
Atp7a¼ copper-transporting ATPase 1
CA1¼Cornus Ammonis 1
CA3¼Cornus Ammonis 3
CaM¼ calmodulin
CNQX¼ 6-cyano-7-nitroquinoxaline-2,3-dione
coIP¼ co-immunoprecipitation
CZ¼ cuprizone
DAPI¼ 4¢,6-diamidino-2-phenylindole
DG¼ dentate gyrus
DMSO¼ dimethyl sulfoxide
EGTA¼ ethylene glycol tetraacetic acid
GluN1¼NMDAR subunit GluN1
GluN2A¼NMDAR subunit GluN2A
GSNO¼ S-nitrosoglutathione
MD¼Menkes’ disease
MTT¼ 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
NeuN¼ anti-neuronal nuclei marker antibody
NMDA¼N-methyl-d-aspartate
NMDAR¼N-methyl-d-aspartate receptors
NNA¼Nx-nitro-l-arginine
nNOS¼ neuronal nitric oxide synthase
NO¼ nitric oxide
OD¼ optical density
OHC¼ organotypic hippocampal cultures
Prnp+=+, Prnp0=0¼ PrPC wild type, PrPC knockout
PrPC¼ cellular prion protein
PSD95¼ postsynaptic density protein 95
SNO-Cys¼ cysteine S-nitrosylation
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